Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease, with a 5-year survival rate < 10%. Current therapies are poorly effective, thus urging the identification of new therapeutic approaches to face this lethal cancer. The RNA helicase DDX21 was recently shown to be upregulated and to associate with poor prognosis in PDAC. Our study shows that DDX21 is further upregulated in liver metastasis with respect to the primary PDAC lesions, and that depletion of DDX21 triggers autophagy while perturbing the cell cycle progression of PDAC. Together, our data support the oncogenic function of DDX21 in PDAC cells and uncover biological processes and pathways modulated by this RNA helicase.

Leccese, A., Ruta, V., Panzeri, V., Attili, F., Spada, C., Cianfanelli, V., Sette, C., DDX21 Controls Cell Cycle Progression and Autophagy in Pancreatic Cancer Cells, <<CANCERS>>, 2025; 17 (4): N/A-N/A. [doi:10.3390/cancers17040570] [https://hdl.handle.net/10807/313333]

DDX21 Controls Cell Cycle Progression and Autophagy in Pancreatic Cancer Cells

Leccese, Adriana
Primo
;
Ruta, Veronica;Panzeri, Valentina;Attili, Fabia;Spada, Cristiano;Sette, Claudio
Ultimo
2025

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease, with a 5-year survival rate < 10%. Current therapies are poorly effective, thus urging the identification of new therapeutic approaches to face this lethal cancer. The RNA helicase DDX21 was recently shown to be upregulated and to associate with poor prognosis in PDAC. Our study shows that DDX21 is further upregulated in liver metastasis with respect to the primary PDAC lesions, and that depletion of DDX21 triggers autophagy while perturbing the cell cycle progression of PDAC. Together, our data support the oncogenic function of DDX21 in PDAC cells and uncover biological processes and pathways modulated by this RNA helicase.
2025
Inglese
Leccese, A., Ruta, V., Panzeri, V., Attili, F., Spada, C., Cianfanelli, V., Sette, C., DDX21 Controls Cell Cycle Progression and Autophagy in Pancreatic Cancer Cells, <<CANCERS>>, 2025; 17 (4): N/A-N/A. [doi:10.3390/cancers17040570] [https://hdl.handle.net/10807/313333]
File in questo prodotto:
File Dimensione Formato  
cancers-17-00570-v2.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 3.48 MB
Formato Adobe PDF
3.48 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/313333
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact